Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 6, 2025

Brilliant Violet 421(TM) anti-T-bet

RRID:AB_10896427
Type: Antibody

Proper Citation

(BioLegend Cat# 644815, RRID:AB_10896427)

Antibody Information

URL: http://antibodyregistry.org/AB_10896427

Proper Citation: (BioLegend Cat# 644815, RRID:AB_10896427)

Target Antigen: T-bet

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: ICFC

Antibody Name: Brilliant Violet 421(TM) anti-T-bet

Description: This monoclonal targets T-bet

Target Organism: Human, Mouse

Clone ID: Clone 4B10

Antibody ID: AB_10896427

Vendor: BioLegend

Catalog Number: 644815

Alternative Catalog Numbers: 644832, 644816

Record Creation Time: 20231110T063643+0000

Record Last Update: 20241115T122959+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-T-bet.

No alerts have been found for Brilliant Violet 421(TM) anti-T-bet.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Nagai M, et al. (2024) Sugar and arginine facilitate oral tolerance by ensuring the functionality of tolerogenic immune cell subsets in the intestine. Cell reports, 43(7), 114490.

Basavaraja R, et al. (2024) PARP11 inhibition inactivates tumor-infiltrating regulatory T cells and improves the efficacy of immunotherapies. Cell reports. Medicine, 5(7), 101649.

Dean JW, et al. (2023) The aryl hydrocarbon receptor cell intrinsically promotes resident memory CD8+ T cell differentiation and function. Cell reports, 42(1), 111963.

Chandra A, et al. (2023) Quantitative control of Ets1 dosage by a multi-enhancer hub promotes Th1 cell differentiation and protects from allergic inflammation. Immunity, 56(7), 1451.

Gadwa J, et al. (2023) Selective targeting of IL2R?? combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC. Cell reports. Medicine, 4(8), 101150.

Song W, et al. (2022) Development of Tbet- and CD11c-expressing B cells in a viral infection requires T follicular helper cells outside of germinal centers. Immunity, 55(2), 290.

Hailemichael Y, et al. (2022) Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer cell, 40(5), 509.

Jiang Y, et al. (2022) Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade. Cell reports, 41(4), 111553.

McLane LM, et al. (2021) Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 T cells. Cell reports, 35(6), 109120.

Di Pilato M, et al. (2021) CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell, 184(17), 4512.

Gerber AN, et al. (2021) The subunits of IL-12, originating from two distinct cells, can functionally synergize to protect against pathogen dissemination in vivo. Cell reports, 37(2), 109816.

Wang HQ, et al. (2021) Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment. Cancer research, 81(11), 3079.

Morris AB, et al. (2020) Signaling through the Inhibitory Fc Receptor Fc?RIIB Induces CD8+ T Cell Apoptosis to Limit T Cell Immunity. Immunity, 52(1), 136.

Berrien-Elliott MM, et al. (2019) MicroRNA-142 Is Critical for the Homeostasis and Function of Type 1 Innate Lymphoid Cells. Immunity, 51(3), 479.

Saleh MM, et al. (2019) Colitis-Induced Th17 Cells Increase the Risk for Severe Subsequent Clostridium difficile Infection. Cell host & microbe, 25(5), 756.

Schreurs RRCE, et al. (2019) Human Fetal TNF-?-Cytokine-Producing CD4+ Effector Memory T Cells Promote Intestinal Development and Mediate Inflammation Early in Life. Immunity, 50(2), 462.

Hirota K, et al. (2018) Autoimmune Th17 Cells Induced Synovial Stromal and Innate Lymphoid Cell Secretion of the Cytokine GM-CSF to Initiate and Augment Autoimmune Arthritis. Immunity, 48(6), 1220.

Roybal KT, et al. (2016) Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell, 167(2), 419.